PD-L1/CD47 TUMOR DIRECTED B-BODYTM BISPECIFIC ANTIBODIES DEMONSTRATING SIGNIFICANT ANTITUMOR ACTIVITY WITH NO TOXICITY IN PRECLINICAL MODELS

被引：0

作者：

Kantak, Seema ^{[1
]}

Glaser, Bryan ^{[2
]}

Wetter, Justin ^{[2
]}

Sim, Bee-Cheng ^{[1
]}

Higaki, Jeff ^{[1
]}

Beal, Jacob ^{[2
]}

Ollerman, Sara ^{[2
]}

Pulukkunat, Dileep ^{[2
]}

Bawadekar, Mandar ^{[2
]}

Kaplan, Charles ^{[1
]}

Lamb, Peter ^{[1
]}

Hammer, Bonnie ^{[2
]}

机构：

[1] Exelixis Inc, Alameda, CA USA

[2] Invenra Inc, Madison, WI USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0630

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630

引用

页码：A378 / A378

页数：1

共 50 条

[21] Correction: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity
Po-Lin Huang
Hung-Tsai Kan
Ching-Hsuan Hsu
Hsin-Ta Hsieh
Wan-Chien Cheng
Ren-Yeong Huang
Jhong-Jhe You
Journal of Translational Medicine, 21
[22] MYC regulates the antitumor immune response through CD47 and PD-L1 (vol 352, aaf7984, 2016)
Casey, S. C.
SCIENCE, 2016, 353 (6296) : 229 - 229
[23] Assessment of PD-L1 and CD47 expression together with tumor-associated TILs in resectable early stage NSCLC
Hall, S.
Wang, L.
Marti, T.
Peng, R-W.
Froment, L.
Berezowska, S.
Kocher, G.
Dorn, P.
Schmid, R. A.
ANNALS OF ONCOLOGY, 2016, 27
[24] DUAL CHECKPOINT BLOCKADE OF CD47 AND PD-L1 USING AN AFFINITY-TUNED BISPECIFIC ANTIBODY MAXIMIZES ANTI-TUMOR IMMUNITY AND IMPROVES THERAPEUTIC WINDOW
Chen, Shih-Hsun
Dominik, Pawel
Stanfield, Jessica
Ding, Sheng
Yang, Wenjing
Kurd, Nadia
Llewellyn, Ryan
Heyen, Jonathan
Wang, Carole
Melton, Zea
Lindquist, Kevin
Van Blarcom, Thomas
Chaparro-Riggers, Javier
Salek-Ardakani, Shahram
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A290 - A290
[25] Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells
Christo, Susan N.
Mcdonald, Keely M.
Burn, Thomas N.
Kurd, Nadia
Stanfield, Jessica
Kaneda, Megan M.
Seelige, Ruth
Dillon, Christopher P.
Fisher, Timothy S.
Baaten, Bas
Mackay, Laura K.
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (11)
[26] LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody (mAb), combines tumor microenvironment (TME) targeted delivery (PD-L1) and a single biological high potency effector (CD47)
Finlay, Jonny
Yver, Antoine
Chivers, Simon
Grainger, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[27] In Vivo Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models
Ashizawa, Tadashi
Iizuka, Akira
Kanematsu, Akari
Ando, Takayuki
Maeda, Chie
Miyata, Haruo
Yamashita, Kazue
Ikeya, Tomoatsu
Kikuchi, Yasufumi
Maruyama, Kouji
Nagashima, Takeshi
Urakami, Kenichi
Yamaguchi, Ken
Akiyama, Yasuto
IN VIVO, 2025, 39 (01): : 80 - 95
[28] Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses
Liu, Boning
Guo, Huaizu
Xu, Jin
Qin, Ting
Guo, Qingcheng
Gu, Nana
Zhang, Dapeng
Qian, Weizhu
Dai, Jianxin
Hou, Sheng
Wang, Hao
Guo, Yajun
MABS, 2018, 10 (02) : 315 - 324
[29] A novel pegylated bispecific antibody-drug conjugate (P-BsADC) JY207b targeting cancers co-expressing PD-L1 and CD47
Wen, Yu
Liu, Shumin
Lyu, Weidong
Lei, Yang
Tan, Shuangyu
Wu, Zibin
Yin, Shuqiang
Zhuo, Qiudong
Wu, Dechun
CANCER RESEARCH, 2024, 84 (06)
[30] A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47
Liu, Shumin
Lyu, Weidong
Yin, Shuqiang
Lei, Yang
Zhuo, Qiudong
Zheng, Liling
Sun, Bin
Tan, Shuangyu
Jiang, Lidong
Zhang, Teng
Gao, Bo
Xu, Rui
Huang, Dechang
Li, Yong
Wu, Zibin
Wu, David
Wen, Yvonne Yu
CANCER RESEARCH, 2023, 83 (07)

← 1 2 3 4 5 →